Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: buzzcut who wrote (79)	11/14/1997 4:46:00 AM
From: geewiz	Read Replies (1) \| Respond to of 534

Good Morning everyone, I was very busy and tried to listen to the call while running some machinery so I did't follow everything. O'Shea opened with reading the 2nd quarter press release, followed by Peggy Miller reporting the numbers, followed by a gentleman from Elan reporting on the glucose monitoring project. There were six questions. The first delt with progress on the distribution agreement; it was asked by an analyst from Flinn and Meyer(???). Jim said there were several agreements in the works, one in particular he mentioned was for a drug named Vidicane or Lidicane; sorry I'll have to call Peggy to clarify that name. Another question dealt with progress from the Roche deal. Jim said there were 4 people from Roche at the plant recently and the application in taking longer due to the drug approval being split into an adult approval and child approval, but clinicals were on track and looking for market introduction next year. Another question from a Paine Webber person asked about expanding the flue vaccine program. Jim said "we learned a lot" this season, next year BJCT will coordinate the effort more closely with local managers because the reception was spotty(that's not the adjective he used but I remember it was something like that)due to turnout being dependent on the local WallMart's promotion. He also said we are targeting other vaccines than flue: none mentioned. The guy from Flinn Meyer came back with a question on the NYC hepatitis vaccine program. Jim said the deputy commissioner of health said "they willl never go back to needles". Then he added that one of the possible vaccines we will be packaging is for MMR mumps measles and rubeola. That's a significant market. Sombody asked a question about what milestones we should expect in the comming joint venture. Jim defered to the gentleman from Elan who's name I forget. He said there is a proof of concept period that extends to the end of March at which time the joint venture will assume all "burden" of futher development. The 1st quarter of 98 will see human trials to confirm results already attained from animal trials. "Pivotal trial in early99". The last question I remember was how the 3rd quarter will look. Jim said "Third quarter is usually a difficult quarter" because our order decline after the flue sales. He said we are marketing "agressively" with several pharmas, metioned Athena Nurosciences(sub of ELan) had visited recently and they had two drugs that may lead to BJCT applications. At some point in the presentation Jim discussed the costs of the Biojector and said our success in mass distribution rests on the market understanding the total cost of applications, not the purchase price of the Biojector. He said we will eventually get this cost to less than the cost of needles. I can only imagine he is including bio-hazard disposal and insurance liability costs of the needle. My take is that the CC was intended to explain the really bad numbers that our 15 million purchase of Elan technology had created. I personally don't expect any significant pharma agreement untill we get the ISO 9000 approval. I reserve the right to have misunderstood or forgot any or all of the above, and if someone elce listened in or has other information please correct omissions or errors. regards, art